Turn this list into pipeline.
Genomics Companies in the UK: 100+ Active Firms (2026)
Genomics companies in the UK develop sequencing, analysis and precision-medicine services for healthcare and life-science customers.
Buying centres cluster around laboratory and sequencing operations, clinical genomics teams, pharmaceutical research groups and informatics functions that need interpretable molecular evidence rather than general health-administration software. The customer base is mostly business-to-business, with healthcare, research and life-science buyers assessing tools through scientific validity, workflow fit and evidence of repeatable delivery. Engagements tend to be specialist and consultative: contracted analysis, retained bioinformatics support, laboratory-service agreements and precision-medicine projects, often with procurement led jointly by scientific, clinical and commercial stakeholders.
Read more
There are 168 actively trading genomics firms in the UK, making this a specialist cohort rather than a broad healthcare-services category. Reported employment totals 1,282 people, concentrated in companies that publish staff numbers rather than in a long tail of consumer-facing providers. Commercial maturity is uneven: 16 firms report turnover above £5M, while 21 have been incorporated since 2022. That mix fits a market in which laboratory capability, clinical credibility and pharmaceutical customer access matter as much as software distribution.
Activity-based regulation matters more than the sector label. A firm offering research-only bioinformatics faces a different assurance burden from one supporting molecular diagnostics, clinical interpretation or patient stratification for drug development. Buyers in healthcare, pharmaceutical and research settings tend to test claims through validation evidence, sample governance, reproducibility and information-security review. That pushes many suppliers towards narrower use cases, where the intended user, biological sample type and decision pathway can be described precisely.
Commercial development appears likely to stay selective. Firms with defensible laboratory workflows or analysis methods tend to have clearer routes into healthcare and pharmaceutical budgets, but sales cycles remain tied to validation, procurement and clinical confidence. The thinner scale-up layer suggests that many businesses may remain specialist providers rather than broad platforms. Consolidation also appears plausible where adjacent capabilities, such as sequencing, interpretation and decision-support tooling, need to be packaged for buyers that prefer fewer suppliers and clearer accountability.
168
Active firms
2026
16
Over £5M
Revenue cohort
21
Since 2022
Newer incorporations
Key facts
About 9% of the trading cohort reports turnover above £5M (16 of 168 firms) — the rest sits below that revenue band.
12% of the cohort was incorporated since 2022 (21 firms), so a sizeable share is in its first few filing cycles.
Genomics suppliers sell sequencing, analysis and precision-medicine services to healthcare and life-science customers that do not want to build every capability in-house.
Commercial models tend to split between service-led sequencing, specialist interpretation and software-supported clinical or research workflows.
Healthcare use cases put genomic information close to clinical governance, data-protection and information-security requirements.
Precision-medicine work depends on the practical link between genomic information, interpretation and its use in patient or research settings.
Top UK genomics companies
Congenica Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops software platforms for analysis and clinical interpretation of genomic sequencing data. Provides automated decision-support tools used by laboratories, hospitals and researchers to diagnose…
Serves B2B and public-sector healthcare markets: NHS genomic services, clinical laboratories, academic medical centres, hospitals and biopharmaceutical companies worldwide, including rare disease,…
Financial Health
DistressedDistressed · -52% CAGR over 1y
Location
EDINBURGH GENETICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides next-generation sequencing products and genomic laboratory services, including library preparation kits, whole genome and exome sequencing, RNA‑seq, metagenomics and bioinformatics. Also…
Serves life science researchers, clinical diagnostic laboratories, clinical trial teams and product developers in healthcare, biotech, agriculture and conservation.
Financial Health
DistressedDistressed · -29% CAGR over 4y
Location
WREN LABORATORIES LIMITED
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsDevelops and performs mRNA‑based liquid biopsy diagnostic tests for cancer detection and monitoring. Provides multi‑gene expression assays including NETest and PROSTest for neuroendocrine and…
Serves cancer care providers, oncologists and patients, plus biopharma and research teams involved in precision oncology, drug development and companion diagnostics.
Financial Health
StableStable · -51% CAGR over 6y
Location
Trajectory
3y · 2023–NowDevelops and supplies genomic analysis products for clinical and research laboratories, including FISH probes, next‑generation sequencing panels, microarray systems and analysis software used to…
Serves clinical and research laboratories, hospital cytogenetics and oncology diagnostics teams, and precision medicine partners developing clinical trial assays and CDx programmes.
Financial Health
Insufficient historyInsufficient history
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and supplies genomic analysis products including FISH probes, next‑generation sequencing panels and aCGH arrays, with associated software and kits used by clinical and research laboratories…
Sells to clinical and research laboratories, including cytogenetics, haematology, oncology and rare disease testing teams. Also serves precision medicine and biopharma partners running clinical trial…
Financial Health
DistressedDistressed · -45% CAGR over 1y
Location
Develops and supplies genomic analysis products including FISH probes, next‑generation sequencing panels and microarray systems for detecting genetic biomarkers in cancer, cytogenetics and rare…
Serves clinical and research laboratories, cytogenetics and molecular genetics teams, oncology and rare disease diagnostics departments, hospitals, academic medical centres, and precision medicine…
Financial Health
Insufficient historyInsufficient history
Location
Develops genomic and epigenomic analysis technologies, including multiomics sequencing workflows, reagents and software that enable simultaneous detection of genetic bases and DNA methylation markers…
Sells to life science researchers, genomics labs, biotech and diagnostic developers studying cancer, neurodegeneration, ageing, precision medicine, liquid biopsy and prenatal testing.
Location
Informed Genomics Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies next‑generation sequencing (NGS) panels, liquid biopsy kits, and cfDNA sample collection and extraction products for genomic research and clinical oncology. Also provides…
Serves genomic healthcare professionals, clinical laboratories, oncology teams and research organisations working in cancer, hereditary disease and translational genomics.
Financial Health
StrongStrong
Location
Almac Diagnostic Services
Provides diagnostic and genomic testing services to support biomarker-driven clinical trials and precision medicine. Offers sample management, sequencing, biomarker and companion diagnostic…
Serves biopharma and biotech companies developing precision medicine programmes, especially clinical trial, biomarker, companion diagnostic and genomic research teams; also works with health…
Location
Develops and commercialises point‑of‑care pharmacogenetic diagnostic systems. Products include the Genedrive molecular testing platform and assays detecting genetic variants such as MT‑RNR1 and…
Serves NHS organisations, hospitals and clinical teams in emergency care, neonatal intensive care and stroke services, alongside healthcare partners adopting point-of-care pharmacogenetic diagnostics.
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides bioinformatics data analysis and biological interpretation for pharmaceutical, biotechnology and academic research. Analyses genomic, transcriptomic, proteomic and other biological datasets,…
Serves pharmaceutical and biotechnology companies, CROs, life science researchers and academic organisations undertaking drug discovery, development and applied biological research.
Financial Health
StableStable · 2% CAGR over 2y
Location
Edinburgh Genetics
Trajectory
4y · 2021–NowDevelops in‑vitro diagnostic medical devices and provides genomic sequencing services, including whole genome, exome, targeted and RNA sequencing, metagenomics and bioinformatics. Also supports…
Serves life science, healthcare and diagnostics organisations, including clinical trial sponsors, genomic laboratories, biotech researchers, and teams in agriculture, conservation, oncology,…
Financial Health
Insufficient historyInsufficient history
Location
Develops semiconductor-based DNA sequencing technology and diagnostic platforms for rapid genomic analysis at the point of care. Builds microchip sequencing systems and tests for detecting infectious…
Targets hospitals, clinicians and clinical laboratories, especially teams managing infectious disease, sepsis and antimicrobial resistance, with relevance to healthcare systems and public health…
Location
HUWEL LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures molecular diagnostic products including RT‑PCR test kits, nucleic acid amplification devices, oligonucleotides, enzymes, reagents, extraction kits and laboratory plasticware…
Sells B2B to clinical diagnostic laboratories, hospitals, public health and TB testing programmes, point-of-care providers, and life sciences research teams in diagnostics, therapeutics and vaccine…
Financial Health
StrongStrong · Hiring · 26% CAGR over 4y
Location
THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides genomic sequencing analysis platforms for infectious disease surveillance, analysing pathogen genomes to identify species, lineages, related isolates, and drug resistance in organisms…
Serves public health agencies, clinical and research laboratories, and healthcare organisations involved in infectious disease surveillance and genomic sequencing, particularly teams working on…
Financial Health
StableStable · -7% CAGR over 2y
Location
Rarecan Limited
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsProvides cancer genetic testing and clinical trial support services. Collects and analyses molecular and clinical data to help patients and clinicians identify relevant research studies, treatment…
Serves people with cancer, especially rare cancer patients, and their clinicians seeking genetic insight, research participation, clinical trial options and treatment information beyond standard care.
Financial Health
WeakWeak · 0% CAGR over 4y
Location
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies molecular diagnostic tests based on qPCR and next‑generation sequencing. Offers singleplex and multiplex qPCR kits, pre‑plated panels, and sequencing assays for detecting…
Serves clinical, veterinary, food and water testing laboratories, research scientists, and organisations developing laboratory-developed tests using qPCR or NGS.
Financial Health
StrongStrong · Growing, Hiring · 34% CAGR over 2y
Location
LGC Genomics
Develops and supplies genomics and molecular biology tools, including genotyping assays, DNA reference materials, sequencing reagents and related services for research, clinical diagnostics and…
Serves B2B and public-sector customers in life sciences, diagnostics, genomics, agriculture, environmental testing and laboratory assurance, including clinical labs, researchers, breeders, regulatory…
Location
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies diagnostic DNA testing kits, reagents and analysis tools for clinical laboratories. Products support genetic testing in areas including transplantation monitoring, oncology,…
Serves clinical and genetic diagnostic laboratories, including transplant, oncology, hematology and reproductive health labs, plus specialist distributors worldwide.
Financial Health
StrongStrong · Profitable, Hiring · 41% CAGR over 2y
Location
Tagomics Ltd
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops epigenomic and multiomic profiling technology for disease research and diagnostics. Uses sequencing, bioinformatics and machine learning to identify genetic, epigenetic and fragmentomic…
Targets B2B life-science and healthcare organisations, including clinical diagnostics labs, genomics researchers and industry partners developing disease profiling and cancer detection applications,…
Financial Health
StrongStrong · Hiring · 77% CAGR over 2y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops blood-based diagnostic tests for early detection of multiple cancers. Uses next-generation sequencing and machine learning to analyse circulating DNA signals, and conducts clinical studies…
Serves healthcare providers and systems, employers, insurers, public-sector health programmes and biopharma partners involved in cancer screening and precision oncology.
Financial Health
DistressedDistressed · -67% CAGR over 4y
Location
Sonrai Analytics
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cloud-based analytics software for precision medicine research. Provides tools and pipelines to integrate genomic, multi‑omic and imaging data, supporting biomarker discovery, patient…
Serves B2B precision medicine and biopharma organisations, including scientists, clinicians and drug development teams working on target discovery, biomarker development, clinical trials and patient…
Financial Health
StrongStrong · Hiring · 40% CAGR over 4y
Location
SOPHIA GENETICS LIMITED
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops cloud-based software that uses AI to analyse genomic and medical imaging data. Provides a platform for clinicians, laboratories and biopharma companies to interpret data, support diagnosis…
Serves healthcare providers and BioPharma companies, including oncologists, radiologists, pathologists, geneticists, lab technicians and bioinformaticians working in cancer, rare disease and…
Financial Health
HealthyHealthy · Hiring · 15% CAGR over 5y
Location
MICROBIAL GENOMICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides microbial DNA sequencing services for research, including whole‑genome, metagenomic and plasmid sequencing using Illumina and Oxford Nanopore platforms. Includes DNA extraction,…
Serves academic researchers, university labs, NHS/clinical scientists and veterinary or life-science research groups needing microbial genomics support, with pricing aimed at project-based and volume…
Financial Health
HealthyHealthy · -62% CAGR over 4y
Location
MC DIAGNOSTICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular diagnostic assays and instruments for immunogenetics, transplantation and transfusion testing. Provides HLA typing services, multiplex assay development, microarray…
Serves healthcare and laboratory organisations in the UK and Ireland, including transplant and transfusion diagnostics labs, blood banks, immunogenetics, microbiology and human genetics teams.
Financial Health
StableStable · 0% CAGR over 4y
Location
Precisionlife
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops AI‑based analytics for precision medicine, analysing genetic and clinical data to identify disease mechanisms and biomarkers for chronic conditions. Supports diagnostics, patient…
Serves B2B healthcare and diagnostics organisations, pharmaceutical and biotech drug developers, and clinical trial teams working in complex chronic diseases and precision medicine.
Financial Health
StrongStrong · Hiring · 25% CAGR over 6y
Location
AM DIAGNOSTICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures molecular diagnostic instruments, PCR and RT‑qPCR assay kits for detecting infectious diseases, genetic mutations, sexually transmitted infections and foodborne pathogens. Also supplies…
Serves clinical diagnostic laboratories, healthcare providers, research organisations, veterinary testing providers and food safety laboratories requiring molecular assays, instruments, PCR reagents…
Financial Health
WeakWeak · 0% CAGR over 4y
Location
Oxford Cancer Biomarkers Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and commercialises biomarker-based diagnostic and prognostic tests for colorectal cancer. Products analyse genetic, clinical and pathology data to assess chemotherapy toxicity risk, predict…
Serves oncologists, oncology clinics, hospitals and diagnostic partners involved in colorectal cancer screening, prognosis and chemotherapy decision-making, with patients accessing testing through…
Financial Health
DistressedDistressed · -45% CAGR over 3y
Location
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops and commercialises blood-based multi‑cancer early detection tests, including the Galleri test, using next-generation sequencing and machine learning to identify cancer signals in DNA from…
Serves healthcare systems, clinicians and public health organisations, and reaches individuals through employer, life insurance and fire department screening programmes; also partners with biopharma…
Financial Health
StrongStrong · Hiring · 111% CAGR over 4y
Location
TWIST BIOSCIENCE UK LTD
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies synthetic DNA products and tools for research and biotechnology, including gene synthesis, oligo pools, NGS target enrichment panels, variant libraries, and reagents used in…
Sells to biotech and pharmaceutical R&D teams, academic and clinical research labs, diagnostics developers and agricultural biotech organizations working in drug discovery, oncology, infectious…
Financial Health
HealthyHealthy · Profitable · 3% CAGR over 2y
Location
PLASMIDSAURUS LTD
Trajectory
1y · 2025–NowProvides DNA and RNA sequencing services for research, including whole plasmid, amplicon, RNA‑seq, whole genome, AAV and microbiome sequencing. Accepts biological samples and returns analyzed…
Sells to scientific researchers and R&D teams needing sequencing services, including biotech startups, pharmaceutical companies, academic and research labs, and independent scientists or biohackers.
Financial Health
Insufficient historyInsufficient history
Location
Genetic Signatures
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises molecular diagnostic products for clinical laboratories, including multiplex real-time PCR assays and sample processing technology. Supplies EasyScreen pathogen detection…
Sells to hospital, pathology and clinical laboratories needing high-throughput molecular infectious disease testing, including healthcare providers and lab teams screening gastrointestinal,…
Financial Health
HealthyHealthy · Hiring · 6% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops AI software that analyses H&E‑stained tissue images to infer molecular and multi‑omics biomarker profiles. The technology provides rapid tissue analysis for hospitals, laboratories, and…
Sells to hospitals, pathology labs and research organisations needing tissue-based molecular profiling, and serves drug development teams in biotech and pharma. Targets clinical diagnostics and…
Financial Health
WeakWeak · Hiring · 3% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops computational and machine learning software for oncology, analysing molecular and clinical data to predict patient response to cancer therapies. Provides a platform for visualising datasets,…
Serves biopharma and oncology research teams, plus clinical research users developing cancer therapies. Targets partners using molecular and clinical data for therapeutic development, translational…
Financial Health
StrongStrong · Growing, Hiring · 37% CAGR over 4y
Location
DARWIN HEALTH LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops computational biology technologies and algorithms for precision oncology, analysing tumour regulatory networks to identify diagnostic biomarkers, predict effective drug combinations, and…
Serves a mix of B2C and B2B customers: individual cancer patients at all disease stages, oncology clinicians or care teams, and pharmaceutical companies with cancer drug development pipelines.
Financial Health
StrongStrong
Location
PCR BIO SYSTEMS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies PCR and qPCR reagents for life science research and molecular diagnostics, including DNA polymerases, probe and dye master mixes, reverse transcriptase kits, nucleic acid…
Serves life science researchers, academic and commercial laboratories, molecular diagnostics developers, and NGS/qPCR users in research and diagnostic settings.
Financial Health
DistressedDistressed · -67% CAGR over 4y
Location
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsDevelops polymer-based materials for capturing cell‑free DNA (cfDNA) from biological fluids. Its msX polymers can be applied to beads, foams and surfaces to collect and stabilise samples for liquid…
Serves diagnostics companies, clinical laboratories, research organisations and healthcare providers developing liquid biopsy, non-invasive genetic testing and personalised medicine workflows,…
Financial Health
StrongStrong
Location
HYRIS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular testing technology including miniaturised qPCR instruments, cloud-based software and diagnostic assays. Platforms support genetic analysis and data management for…
Serves laboratories, hospitals and clinics in healthcare diagnostics, plus nutraceutical businesses, food manufacturers and agronomists. Also targets kit developers, research and academic…
Financial Health
DistressedDistressed · -69% CAGR over 5y
Location
SISTEMIC SCOTLAND LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops microRNA‑based molecular diagnostic assays and analytical services for cell and gene therapy research and manufacturing. Provides tests for residual pluripotent stem cells, mycoplasma…
Serves B2B customers in pharmaceutical, biotechnology, and cell and gene therapy research, development, and manufacturing, including teams involved in cell therapy characterisation, quality control,…
Financial Health
StableStable · -5% CAGR over 4y
Location
GENEWIZ UK LIMITED
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsProvides DNA and RNA sequencing and synthesis services for research and clinical applications, including next‑generation sequencing, Sanger sequencing, gene and oligonucleotide synthesis, plasmid DNA…
Serves B2B life sciences researchers and organisations in biotech, pharma, academic, clinical and preclinical research, including genomics, cell and gene therapy, cancer, infectious disease,…
Financial Health
HealthyHealthy · -66% CAGR over 4y
Location
BIO MOLECULAR SYSTEMS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures laboratory instruments and software for life science research and diagnostics, including real‑time PCR cyclers, automated liquid handling systems, and workflow software for…
Sells B2B to clinical diagnostics and life science research laboratories worldwide, including academic institutes, biotech and pharmaceutical teams running genomics, qPCR, NGS library prep and drug…
Financial Health
StrongStrong · Growing, Hiring · 19% CAGR over 4y
Location
Science Care Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies laboratory equipment and provides genomic testing services including whole genome sequencing, whole exome sequencing and targeted panels. Also offers bioanalytical and biopharmaceutical…
Serves B2B and healthcare customers involved in research, drug development and patient care, including laboratories, biopharmaceutical and bioanalytical organisations, and teams needing genomic…
Financial Health
StableStable · 0% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular diagnostic assays and instruments for immunogenetics, transplantation, transfusion and infectious disease testing. Provides HLA typing services, microarray printing,…
Serves clinical laboratories, transplant and transfusion services, blood banks, and healthcare or research organisations in the UK and Ireland needing molecular diagnostics, HLA typing, serology and…
Financial Health
DistressedDistressed
Location
STANDARD BIOTOOLS UK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies genomic and proteomic research technologies, including CyTOF, Hyperion and Biomark systems, along with consumables, reagents and software. Provides laboratory services and tools…
Sells to life sciences research organisations, including translational and clinical researchers, genomics and proteomics labs, and teams working in infectious disease, neuroscience, agrigenomics,…
Financial Health
HealthyHealthy · Hiring · 22% CAGR over 2y
Location
Develops genomic analysis tools and DNA testing services that estimate individuals’ risk of common diseases using polygenic risk scores and large-scale genetic data. Provides health insights…
Serves insurers and underwriting partners, employers, life sciences and pharma companies, researchers, and healthcare providers including the NHS, with end users spanning employees, policyholders and…
Location
Chromition Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostic technologies using Luminspheres fluorescent particles for immunofluorescence imaging and molecular detection. Products include systems for detecting circulating tumour cells in…
Serves healthcare diagnostics organisations, clinical laboratories, pathology teams and life science partners involved in cancer screening, immunofluorescence, HER2 testing and point-of-care genomic…
Financial Health
StrongStrong · Growing, Hiring · 11% CAGR over 4y
Location
KINOMICA LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops phosphoproteomic diagnostic technologies for precision medicine. Creates the KScan platform to analyse protein phosphorylation and signalling pathways, supporting cancer diagnostics, drug…
Sells to clinicians and healthcare providers using precision medicine in cancer care, and to pharmaceutical and biotech R&D teams developing diagnostics, treatment-selection tools, and new drug…
Financial Health
HealthyHealthy · Hiring · 29% CAGR over 1y
Location
SEQUOIA GENETICS LTD
Trajectory
2y · 2025–NowFinancial sub-scores
Computed from 2 filingsProvides research and analytical services using human genetic data, statistical genetics and Mendelian randomization to generate insights on disease biology and support drug target discovery and…
Serves pharmaceutical and biotech companies, life sciences investors and academic groups involved in drug discovery and development, particularly those using human genetic data to assess therapeutic…
Financial Health
StrongStrong · Growing, Hiring · 64% CAGR over 1y
Location
Dxcover Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostic technology for early cancer detection using multi‑omic spectral analysis and machine learning. Provides liquid biopsy testing platforms and assays aimed at identifying cancers…
Serves healthcare systems, clinicians and diagnostic partners working with high-risk cancer patient populations, with partnering aimed at biopharma and diagnostics companies.
Financial Health
StrongStrong · Growing, Hiring · 22% CAGR over 4y
Location
Develops and supplies life science tools, reference standards, genomics reagents, and diagnostic quality controls. Provides proficiency testing, laboratory services, and genetic analysis technologies…
Serves life science and analytical testing organisations worldwide, including clinical diagnostic labs, pharma and biotech researchers, agricultural breeders, food and environmental testing labs, and…
Location
Unlock all 168 leads
Showing 50 of 168 — +118 more with verified decision-maker contacts, live data, and CRM sync.
How UK genomics companies work and how to sell to them
What they do
Genomics firms usually earn through a mix of laboratory services, contracted analysis, bioinformatics support, software licences and precision-medicine project work. Pricing often follows the unit of work: per sample, per analysis, per study, annual licence or retained service agreement. Smaller engagements may start as validation projects or research collaborations, while larger accounts tend to become repeat laboratory-service or informatics contracts once workflows are embedded. The commercial shape is therefore less like general healthcare software and more like specialist scientific delivery, where methods, turnaround times, sample handling and interpretation quality define value.
Who they sell to
Healthcare providers, pharmaceutical research groups, academic research organisations and life-science companies are the main buyers. Typical decision-makers include laboratory directors, clinical genomics leads, heads of bioinformatics, translational medicine teams, R&D sponsors and procurement functions, with information-security and legal review often involved when patient or sample-linked information is handled. Sales are usually direct and consultative rather than self-serve. Many deals move through pilots, validation studies, research-service agreements or framework-style procurement before wider use, because buyers need confidence that a method fits their scientific question, clinical pathway or drug-development programme.
What they buy
Most genomics firms tend to spend on laboratory equipment support, cloud computing, data storage, workflow management, quality management, security, CRM, billing, finance, HR and analytics. Bioinformatics-heavy teams may also buy developer tooling, observability, data-pipeline support and specialist recruitment for computational biology, software engineering and scientific operations. Service spend often covers legal review, clinical or research governance, regulatory advice, grant support, marketing to life-science audiences and contract negotiation with healthcare or pharmaceutical customers. Suppliers that understand sample governance, reproducibility, audit trails and scientific buyer committees usually have an easier starting point than those selling generic back-office efficiency alone.
Why and how to sell to them
Buying intent often appears when genomics companies move from research projects into repeat commercial delivery, add clinical or pharmaceutical customers, expand laboratory throughput or hire senior scientific and commercial operators. Common pressures include long validation cycles, complex sample governance, data-security review, specialist hiring, margin control on service work and the need to make analysis reproducible across teams. Outbound messages tend to land better when framed around a specific workflow bottleneck, such as shortening procurement evidence packs, improving auditability, reducing manual handovers or supporting repeat delivery, rather than broad claims about growth or digital maturity.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Related directories
Frequently asked questions
How many genomics companies are there in the UK?↓
What counts as a genomics company in this list?↓
Which are the largest genomics companies in the UK?↓
What do genomics companies in the UK actually do?↓
How does UK genomics compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical genomics companies in the UK?↓
Are these mostly new or established genomics companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 168 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.